41.69BMarket Cap18.63P/E (TTM)
49.250High47.550Low3.58MVolume49.050Open49.000Pre Close173.23MTurnover0.41%Turnover Ratio18.63P/E (Static)865.86MShares55.00052wk High8.05P/B41.69BFloat Cap30.30052wk Low--Dividend TTM865.86MShs Float69.900Historical High--Dividend LFY3.47%Amplitude11.500Historical Low48.381Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
AKESO Stock Forum
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK)$ ...
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
No comment yet